Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-10 of 19 (Search time: 0.005 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2014Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignanciesPatel, G.; Jain, K.; Kumar, R.; Strickland, A.; Pellegrini, L.; Slavotinek, J.; Eaton, M.; McLeay, W.; Price, T.; Ullah, S.; Koczwara, B.; Kichenadasse, G.; Karapetis, C.
2014The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17Sommeijer, D.; Karapetis, C.; Zalcberg, J.; Tu, D.; Jonker, D.; Simes, J.; Tebbutt, N.; Yip, D.; Price, T.; O'Callaghan, C.
2014Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancerJonker, D.; Karapetis, C.; Harbison, C.; O'Callaghan, C.; Tu, D.; Simes, R.; Malone, D.; Langer, C.; Tebbutt, N.; Price, T.; Shapiro, J.; Siu, L.; Wong, R.; Bjarnason, G.; Moore, M.; Zalcberg, J.; Khambata-Ford, S.
2014Nanostructured polystyrene well plates allow unbiased high-throughput characterization of circulating tumor cellsWan, Y.; Winter, M.; Delalat, B.; Hardingham, J.; Grover, P.; Wrin, J.; Voelcker, N.; Price, T.; Thierry, B.
2014The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trialsSegelov, E.; Chan, D.; Shapiro, J.; Price, T.; Karapetis, C.; Tebbutt, N.; Pavlakis, N.
2014The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX studyCarter, H.; Zannino, D.; John Simes, R.; Schofield, D.; Howard, K.; Zalcberg, J.; Price, T.; Tebbutt, N.
2014Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tian, Y.; Sidhu, R.
2014Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 studyPrice, T.; Peeters, M.; Kim, T.; Li, J.; Cascinu, S.; Ruff, P.; Suresh, A.; Thomas, A.; Tjulandin, S.; Zhang, K.; Murugappan, S.; Sidhu, R.
2014Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancerHocking, C.; Price, T.
2014Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013Price, T.; Segelov, E.; Burge, M.; Haller, D.; Tebbutt, N.; Karapetis, C.; Punt, C.; Pavlakis, N.; Arnold, D.; Gibbs, P.; Shapiro, J.